[go: up one dir, main page]

WO2006060051A3 - Enzyme chimeras and methods of their use for the treatment of infection by bacillus anthracis - Google Patents

Enzyme chimeras and methods of their use for the treatment of infection by bacillus anthracis Download PDF

Info

Publication number
WO2006060051A3
WO2006060051A3 PCT/US2005/032566 US2005032566W WO2006060051A3 WO 2006060051 A3 WO2006060051 A3 WO 2006060051A3 US 2005032566 W US2005032566 W US 2005032566W WO 2006060051 A3 WO2006060051 A3 WO 2006060051A3
Authority
WO
WIPO (PCT)
Prior art keywords
infection
bacillus anthracis
treatment
methods
chimeras
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/032566
Other languages
French (fr)
Other versions
WO2006060051A2 (en
Inventor
L L Houston
Scott Sherrill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arizeke Pharmaceuticals Inc
Original Assignee
Arizeke Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arizeke Pharmaceuticals Inc filed Critical Arizeke Pharmaceuticals Inc
Publication of WO2006060051A2 publication Critical patent/WO2006060051A2/en
Publication of WO2006060051A3 publication Critical patent/WO2006060051A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides chimeras of lytic enzymes selective for Bacillus anthracis that can be directed to lung tissue of a subject infected with the bacterium, or at risk for such an infection. Since the lytic enzyme is capable of selectively killing the bacterium, the chimeras are useful for delivering therapeutics to lung tissue of a subject to treat or prevent infection by Bacillus anthracis.
PCT/US2005/032566 2004-09-13 2005-09-12 Enzyme chimeras and methods of their use for the treatment of infection by bacillus anthracis Ceased WO2006060051A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60977104P 2004-09-13 2004-09-13
US60/609,771 2004-09-13

Publications (2)

Publication Number Publication Date
WO2006060051A2 WO2006060051A2 (en) 2006-06-08
WO2006060051A3 true WO2006060051A3 (en) 2006-11-23

Family

ID=36565471

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/032566 Ceased WO2006060051A2 (en) 2004-09-13 2005-09-12 Enzyme chimeras and methods of their use for the treatment of infection by bacillus anthracis

Country Status (1)

Country Link
WO (1) WO2006060051A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007081906A2 (en) * 2006-01-06 2007-07-19 Amgen Inc. Purification by column-chromatography using eluants containing organic solvents
US20110059514A1 (en) * 2007-01-09 2011-03-10 David Alexander Schofield Yeast Biocatalysts for Degradation of Biowarfare Agents
US8927244B2 (en) 2007-10-01 2015-01-06 Guild Associates, Inc. Organophosphorus hydrolase

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050036951A1 (en) * 2003-01-09 2005-02-17 Arizeke Pharmaceuticals, Inc. Methods of treating lung diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050036951A1 (en) * 2003-01-09 2005-02-17 Arizeke Pharmaceuticals, Inc. Methods of treating lung diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHUCH R. ET AL., NATURE, vol. 418, 2002, pages 884 - 889, XP002903133 *

Also Published As

Publication number Publication date
WO2006060051A2 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
WO2003101397A3 (en) Tetravalent dengue vaccines
MY158447A (en) Compounds modulating c-fms and/or c-kit activity and uses thereof
WO2001019385A3 (en) The use of bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of various illnesses
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
WO2008100292A3 (en) Modified vaccinia virus strains for use in diagnostic and therapeutic methods
WO2003093462A3 (en) Immobilisation and stabilisation of virus
WO2003097794A3 (en) Universal-tagged oligonucleotide primers and methods of use
WO2005097119A3 (en) Pten inhibitors
WO2005034855A3 (en) Photodynamic inactivation of bacterial spores
WO2012064667A3 (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
WO2009143150A3 (en) Intestinal alkaline phosphatase modulators and uses thereof
WO2006015035A8 (en) Useful compounds for hpv infection
WO2006062596A3 (en) RNAi MODULATION OF RSV, PIV AND OTHER RESPIRATORY VIRUSES AND USES THEREOF
WO2007107488A3 (en) Vaccine against trypanosoma cruzi infection
WO2005117938A3 (en) Methods of treating ocular conditions
WO2004052236A3 (en) Methods and compositions for treatment of otitis media
WO2008105826A3 (en) Compositions compromising lysostaphin variants and methods of using the same
EP3939599A3 (en) Silicate containing compositions and methods of treatment
WO2007024628A3 (en) Ply-gbs mutant lysins
PL1919466T3 (en) Formulations for treatment of lipoprotein abnormalities comprising a statin and a methylnicotinamide derivative
WO2007047608A3 (en) Fibrin targeted therapeutics
DE602008003199D1 (en) GLUCOSEISOMERASE FOR THE TREATMENT OF FRUCTOSE INCOMPATIBILITY
WO2007107748A3 (en) Inhibition of tumour growth
WO2008097364A3 (en) Use of oritavancin for prevention and treatment of anthrax
WO2006060051A3 (en) Enzyme chimeras and methods of their use for the treatment of infection by bacillus anthracis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC DATED 24.05.07

122 Ep: pct application non-entry in european phase

Ref document number: 05851211

Country of ref document: EP

Kind code of ref document: A2